急诊护理机构中新冠疫苗对有症状和无症状SARS-CoV-2感染的有效性
该回顾性研究在纽约大都市区急诊护理中心对2021年4月14日至10月25日期间接受SARS-CoV-2检测的≥12岁患者进行分析,采用检测阴性设计估算疫苗有效性。结果显示,两剂mRNA疫苗对有症状感染的有效性在德尔塔流行前期为96%,德尔塔流行期降至79%;德尔塔期12-15岁组有效性为85%,高于其他年龄组;既往感染后完全接种者有效性最高。
要点
- 两剂mRNA疫苗对有症状感染的有效性在德尔塔期降至79%(95%CI 77%-81%),低于德尔塔前期的96%(95%CI 95%-97%)。
- 德尔塔期12-15岁组疫苗有效性为85%(95%CI 81%-88%),高于其他年龄组(均<65%)。
- 德尔塔期两剂mRNA-1273疫苗有效性为82%(95%CI 80%-84%),高于BNT162b2疫苗的76%(95%CI 74%-78%)。
核心结论
- 两剂mRNA疫苗对感染的有效性初期很高,但对德尔塔变异株针对两种FDA获批疫苗均显著降低。
研究设计与样本
- 回顾性研究,纳入2021年4月14日至10月25日在纽约大都市区急诊护理中心接受SARS-CoV-2检测的≥12岁患者。
- 采用检测阴性设计,比较接种疫苗组(n=474,805)、部分接种组(n=87,834)和未接种组(n=369,333)的SARS-CoV-2阳性检测比值,并调整人口学因素和日历时间。
主要发现
- 德尔塔前期两剂mRNA疫苗对有症状感染的有效性为96%(95%CI 95%-97%),德尔塔期降至79%(95%CI 77%-81%)。
- 德尔塔期12-15岁组疫苗有效性为85%(95%CI 81%-88%),高于其他年龄组(均<65%)。
- 疫苗有效性估计值按性别和种族/族裔无差异。
- 有既往感染后完全接种的个体对有症状感染的有效性最高。
- 德尔塔期两剂mRNA-1273疫苗有效性为82%(95%CI 80%-84%),高于BNT162b2疫苗的76%(95%CI 74%-78%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is critical to monitor changes in vaccine effectiveness against COVID-19 outcomes for various vaccine products in different population subgroups. METHODS: We conducted a retrospective study in patients ≥12 years who underwent testing for SARS-CoV-2 virus from April 14 through October 25, 2021, at urgent care centers in the New York metropolitan area. Patients self-reported vaccination status at the time of testing. We used a test-negative design to estimate vaccine effectiveness (VE) by comparing odds of a positive test for SARS-CoV-2 infection among vaccinated (n = 474,805), partially vaccinated (n = 87,834), and unvaccinated (n = 369,333) patients, adjusted for demographic factors and calendar time. RESULTS: VE against symptomatic infection after 2 doses of mRNA vaccine was 96% (95% Confidence Interval: 95%, 97%) in the pre-delta period and reduced to 79% (95% CI: 77%, 81%) in the delta period. In the delta period, VE for 12-15-year-olds (85%; [95% CI: 81%, 88%]) was higher compared to older age groups (<65% for all other age groups). VE estimates did not differ by sex and race/ethnicity. VE against symptomatic infection was the highest for individuals with a prior infection followed by full vaccination. VE against symptomatic infection after the 2-dose mRNA-1273 vaccine (82% [95% CI: 80%, 84%]) was higher compared to the BNT162b2 vaccine (76% [95% CI: 74%, 78%]) in the delta period. VE after 1-dose of the Ad26.COV2.S vaccine was the lowest compared to other vaccines (19% [95% CI: 15%, 23%]) in the delta period. CONCLUSIONS: VE against infection after two doses of the mRNA vaccines was high initially, but significantly reduced against the delta variant for both FDA-approved vaccines.
引用
- Rane MS, Robertson MM, Kulkarni SG, et al. Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting. Vaccine. 2022. PMID: 36588007. doi:10.1016/j.vaccine.2022.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。